BIOMARKER TESTING
THE RIGHT TREATMENT
FOR THE RIGHT PATIENT
AT THE RIGHT TIME

WHAT IS BIOMARKER TESTING?
Biomarker testing is often used to help determine the best treatment for a patient.
- Biomarker testing is the analysis of a patient's tissue, blood, or other biospecimen for the presence of a biomarker.
- Biomarker testing is an important step for accessing precision medicine, including targeted therapies that can lead to improved survivorship and better quality of life for cancer patients.
- While most current applications of biomarker testing are in oncology and autoimmune disease, there is research underway to benefit patients with other conditions including rare diseases, heart disease, neurological conditions like Alzheimer's disease, infectious diseases, and respiratory illness.

THE IMPORTANCE OF BIOMARKER TESTING

Biomarker testing is often used to help determine the best treatment for a patient.

- **60%** of oncology drugs launched in the past five years require or recommend biomarker testing prior to use.

In 2000:
- **15%** of cancer clinical trials involved biomarkers.

In 2018:
- **55%** of cancer clinical trials involved biomarkers.

BIOMARKER TESTING & HEALTH EQUITY
Not all Florida communities are benefitting from the latest advancements in biomarker testing and precision medicine.
- Patients who are older, Black, uninsured, Medicaid-insured, and/or in rural areas are less likely to be tested for certain guideline-indicated biomarkers for colorectal cancer.
- There are lower rates of testing in community oncology settings versus academic medical centers.

THE BOTTOM LINE
Access to appropriate biomarker testing can help to achieve:
- better health outcomes
- improved quality of life
- reduced costs

Insurance coverage for biomarker testing is failing to keep pace with innovation and advances in treatment.
- Without action, this could increase existing disparities in cancer outcomes by race, ethnicity, income, and geography.

- **66%** of oncology providers reported that insurance coverage is a significant or moderate barrier to appropriate biomarker testing for their patients.
Our organizations are working together to educate the public and policymakers about the importance of biomarker testing.

For questions or to join the coalition, please contact:
Susan Harbin, ACS CAN Florida Sr. Government Relations Director

susan.harbin@cancer.org

770-546-8845

fightcancer.org/FLBiomarkers